Medicenna Therapeutics Corp - MDNAF STOCK NEWS

Medicenna Therapeutics Corp. announced the appointment of MNP LLP as its new auditor, replacing PricewaterhouseCooper LLP. The Former Auditor's report for the two most recently completed financial years showed no reservations or modified opinions. The company's board of directors and audit committee approved the resignation of the Former Auditor and the appointment of MNP. Additionally, Medicenna has engaged Tandem Accounting Group Ltd. to manage its financial reporting and internal bookkeeping requirements on a contract basis.

Medicenna Therapeutics Corp. (MDNA) announced the initiation of enrollment in the combination arm of the Phase 1/2 ABILITY study evaluating MDNA11, a long-acting IL-2 Superkine, in combination with KEYTRUDA for the treatment of advanced solid tumors. The study aims to evaluate the potential synergistic effect of MDNA11 with KEYTRUDA in patients who do not respond or develop resistance to checkpoint therapy. MDNA11 has shown encouraging single-agent activity and is generally well tolerated. The company expects to report initial results from both the monotherapy expansion and combination escalation arms of the Phase 2 study in the first half of 2024.

Medicenna Therapeutics Corp. (MDNA) announces its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023, while continuing to trade on the Toronto Stock Exchange under its symbol MDNA. The OTCQB is the primary platform for U.S. and international companies in the entrepreneurial and development stages, providing a high-quality trading and information experience for U.S. investors.

Medicenna Therapeutics Corp. (TSX: MDNA, OTC: MDNAF) announced the Phase 2b clinical trial results of bizaxofusp, showing a 100% increase in survival benefit in unresectable recurrent glioblastoma (rGBM) patients after a single treatment. The treatment also doubled median overall survival (mOS) to 14.5 months, irrespective of IL4R expression. The data presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting highlights the promising impact of bizaxofusp in the treatment of rGBM.

Medicenna Therapeutics Corp. (MDNA) extends cash runway through Q1 2025, reports positive clinical data readouts for MDNA11 and bizaxofusp. The company also announced financial results for Q2 of fiscal 2024, showing a decrease in cash and cash equivalents compared to the previous quarter.

Medicenna Therapeutics Corp. (MDNA) to present long-term follow-up data from Phase 2b clinical trial of bizaxofusp at SNO 2023 Annual Meeting

Medicenna Therapeutics announced that Dr. Fahar Merchant, its President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 10:00 AM ET. The presentation will provide an overview of the company's immuno-oncology developments, including its promising MDNA11 and MDNA55 assets, focused on cancer treatment. A live webcast will be accessible here. A replay will be available post-event on Medicenna's website.

Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced promising preclinical data for MDNA19-MDNA413, a dual-specific cytokine developed from their BiSKITs™ platform, presented at the AACR Annual Meeting. This innovative therapy selectively activates anti-cancer immune cells while inhibiting pro-tumoral macrophage polarization. Key findings highlighted a 209-fold and 90-fold enhancement in CD8/Treg and NK/Treg ratios, respectively, and effective suppression of IL-13 induced M2a macrophage polarization. Medicenna plans to advance its development and regulatory submissions for MDNA11, another promising superkine therapy.

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the presentation of an abstract during the AACR Annual Meeting 2021 on April 10-15, highlighting early preclinical studies of a novel bispecific Superkine. The abstract, titled Modulation of Immune Responses to Cancer by Bi-specific IL-2/IL-13 Superkines, focuses on an innovative approach combining IL-2 super-agonist with IL-4/IL-13 super-antagonist. The full abstract is available on AACR's website and will be accessible on Medicenna's site post-conference.